Reply: Lymph node density as a surrogate marker for positive lymph nodes

por Polterauer, S, Grimm, C, Reinthaller, A, Tempfer, C
Publicado 2011

Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report

por Paspalj, V., Polterauer, S., Poetsch, N., Reinthaller, A., Grimm, C., Bartl, T.
Publicado 2021

Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer.

por Sliutz, G., Tempfer, C., Winkler, S., Kohlberger, P., Reinthaller, A., Kainz, C.
Publicado 1995

Serum M3/M21 in ovarian cancer patients.

por Tempfer, C., Hefler, L., Haeusler, G., Sliutz, G., Hanzal, E., Reinthaller, A., Kainz, C. H.
Publicado 1997

Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients

por Hefler, L, Tempfer, C, Heinze, G, Mayerhofer, K, Breitenecker, G, Leodolter, S, Reinthaller, A, Kainz, C
Publicado 1999

The impact of lymph node density on survival of cervical cancer patients

por Polterauer, S, Hefler, L, Seebacher, V, Rahhal, J, Tempfer, C, Horvat, R, Reinthaller, A, Grimm, C
Publicado 2010

CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer.

por Tempfer, C., Sliutz, G., Haeusler, G., Speiser, P., Reinthaller, A., Breitenecker, G., Vavra, N., Kainz, C.
Publicado 1998

The prognostic value of CD44 isoform expression in endometrial cancer.

por Tempfer, C., Haeusler, G., Kaider, A., Hefler, L., Hanzal, E., Reinthaller, A., Breitenecker, G., Kainz, C.
Publicado 1998

The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial

por Seebacher, V, Polterauer, S, Grimm, C, Husslein, H, Leipold, H, Hefler-Frischmuth, K, Tempfer, C, Reinthaller, A, Hefler, L
Publicado 2010

Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial

por Seebacher, V, Hofstetter, G, Polterauer, S, Reinthaller, A, Grimm, C, Schwameis, R, Taucher, S, Wagener, A, Marth, C, Concin, N
Publicado 2013

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study

por Sehouli, J, Reinthaller, A, Marth, C, Reimer, D, Reimer, T, Stummvoll, W, Angleitner-Boubenizek, L, Brandt, B, Chekerov, R
Publicado 2014

Nomogram prediction for overall survival of patients diagnosed with cervical cancer

por Polterauer, S, Grimm, C, Hofstetter, G, Concin, N, Natter, C, Sturdza, A, Pötter, R, Marth, C, Reinthaller, A, Heinze, G
Publicado 2012

Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer

por Grimm, C, Hofstetter, G, Aust, S, Mutz-Dehbalaie, I, Bruch, M, Heinze, G, Rahhal-Schupp, J, Reinthaller, A, Concin, N, Polterauer, S
Publicado 2013

Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial

por Seebacher, V, Polterauer, S, Grimm, C, Rahhal, J, Hofstetter, G, Bauer, E-M, Husslein, H, Leipold, H, Marth, C, Reinthaller, A, Concin, N
Publicado 2012

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway

por Pils, D, Pinter, A, Reibenwein, J, Alfanz, A, Horak, P, Schmid, B C, Hefler, L, Horvat, R, Reinthaller, A, Zeillinger, R, Krainer, M
Publicado 2007